WAUKESHA, Wis.--(BUSINESS WIRE)--GE Healthcare will present a new vision for molecular imaging, "Understanding disease. From the beginning," reinforced by its innovative platform of imaging agents and imaging systems at the 56th annual meeting of the Society of Nuclear Medicine, June 13-17, in Toronto, Canada.

"Looking at the future of healthcare, we understood the need to dedicate an entire business segment to molecular imaging," said Terri Bresenham, newly appointed vice president of GE Healthcare's molecular imaging business. "We are in the unique position of providing a complete portfolio of clinically-relevant offerings, from imaging agents to imaging systems. At GE, we have the capability to provide single touch-point solutions to our global customers."

At SNM 2009, GE Healthcare will feature SPECT/CT, PET/CT, radiopharmacy and pre-clinical technologies that address some of the biggest issues facing healthcare providers, such as inaccuracy caused by motion in PET/CT imaging, the need for better visualization of disease and efficient workflow in SPECT/CT, faster throughput for pre-clinical imaging and more consistent and compliant imaging agent production in radiopharmaceuticals.
"We are focused on advancing the field of molecular imaging to help all clinicians see disease earlier than ever before, specifically in the areas of neurodegenerative diseases, cardiology, and oncology, " said Will Downie, molecular imaging leader for GE Healthcare's Medical Diagnostics business. "We are proud to be a leading voice emphasizing the value of molecular imaging and its impact on early diagnosis and treatment."

GE recently launched a company-wide health initiative dubbed "Healthymagination," in line with the renowned, environmentally conscious, Ecomagination program. Healthymagination is focused on sustainable health, enabled by innovation that lowers cost, improves quality and touches more people.

"Our commitment to understanding disease from the beginning and utilizing this understanding for innovation, has the opportunity to revolutionize healthcare," said Bresenham. "At GE, we view innovation as a way to lower the costs in healthcare and improve the quality of outcomes for more people."

Nuclear Medicine

GE showcases one of the greatest nuclear cardiology revolutions in fifty years with its Alcyone Technology, a nuclear cardiology platform combining cadmium zinc telluride (CZT) detectors, focused pin-hole collimation, 3D reconstruction, and stationary data acquisition, to improve workflow, dose management, and overall image quality. Alcyone's focused multi-pinhole collimation has been strategically positioned to view cardiac anatomy and pathology with greater clarity and speed, resulting in scan times as short as 3 minutes. Unlike conventional nuclear imaging, all views are acquired simultaneously during a fully stationary SPECT acquisition, eliminating equipment movement during the scan and reducing the risk of motion artifacts. Available in SPECT (Discovery NM 530c) and SPECT/CT (Discovery NM/CT 570c) configurations, Alcyone technology will take a department and its workflow to new heights.

More HCB News